Feb 23, 2021
BioInvent International Financial Statement January 1 - December 31, 2020
Jan 28, 2021
BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients
Jan 26, 2021
BioInvent has enrolled first patient in a Phase I/IIa trial of the first-in-class anti-TNFR2 antibody BI-1808 for the treatment of patients with solid tumors and CTCL
Jan 20, 2021
BioInvent to host Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin's Lymphoma
Jan 11, 2021
BioInvent streamlines agreement on anti-FcgRllB antibody, BI-1206, ahead of Phase I/II data
Dec 21, 2020
BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors
Dec 09, 2020
Nomination Committee appointed for BioInvent International's Annual General Meeting 2021
Nov 27, 2020
Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020
Nov 27, 2020
BioInvent strengthens Investor Relations
Nov 26, 2020
BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10
Oct 29, 2020
BioInvent Interim Report January 1 - September 30, 2020
Oct 27, 2020
BioInvent licenses anti-FcgRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region
Oct 26, 2020
CTA approval of BioInvent's BI-1808, a first-in-class anti-TNFR2 antibody, sets stage for Phase I/IIa trial
Oct 22, 2020
BioInvent receives EUR2 million milestone from Daiichi Sankyo
Oct 15, 2020
BioInvent to present data on BI-1808, an anti-TNFR2 antibody, at the SITC 35th Anniversary Annual Meeting
Aug 27, 2020
BioInvent Interim Report January 1 - June 30, 2020
Aug 21, 2020
Invitation to presentation of BioInvent's second quarter report 2020 on August 27, 2020
Jun 30, 2020
BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL
Jun 23, 2020
BioInvent Enrolls First Patient in Phase I/IIa Trial of BI-1206 in Combination With KEYTRUDA® for the Treatment of Patients With Solid Tumors
Jun 22, 2020
BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models